Pep IQ
← Pep IQ
Substantial and growing. Humanin is the first member of the mitochondrial-derived peptide (MDP) class — small open reading frame within the mitochondrial 16S rRNA gene. Yen et al. (Aging 2020) showed bi-weekly injections of the HN-S14G analog delayed cognitive decline in middle-aged mice and extended lifespan in worm models. Multiple in vitro and in vivo neuroprotection studies in cell culture and Alzheimer's mouse models (3xTg-AD, APP/PS1) — humanin protects against amyloid-beta toxicity and prevents memory deficits from intracerebroventricular Aβ injection. The HNG analog is more potent than wild-type humanin and is the version most studied therapeutically.
Community use is limited and protocols are not converged. Most experimental use is the HNG analog at bi-weekly to weekly SubQ injections. Doses vary widely between sources because no human PK data exists. Pep IQ does not endorse a specific community protocol — there isn't a credible one to converge on, only individual extrapolation from rodent dosing.
No therapeutic human clinical trials of humanin or HNG have been published. Human evidence is correlative rather than interventional: mitochondrial GWAS (rs2854128 SNP) associates lower circulating humanin with accelerated cognitive aging. Plasma humanin levels are higher in centenarians' offspring (who are themselves more likely to reach centenarian status) and lower in Alzheimer's disease and MELAS patients. These are association studies — they suggest humanin may be a biomarker for healthspan, but they do not prove that exogenous humanin administration in healthy humans produces cognitive or longevity benefits.
Not approved by any regulatory agency. Sold by research-peptide vendors. The HNG analog is the form typically supplied. Mechanism is genuinely novel (MDP class) and the science is ongoing — this is not a settled compound.
Humanin is a genuinely novel and mechanistically interesting peptide class with a real published research base in mice and convincing correlative human data linking circulating levels to longevity. But no therapeutic human trials exist, and the gap between association studies (humanin levels correlate with healthspan) and intervention (giving exogenous humanin produces healthspan gains) is exactly the gap clinical trials exist to close — and they haven't been done. Pep IQ flags this as an experimental compound with promising biology, no validated human protocol, and no human safety data beyond what individual users have generated. Members considering humanin should recognise they are well past the edge of evidence-based use.
Humanin has a remarkable origin story. It was discovered in 2001 by Japanese researchers conducting a cDNA library screen — they were looking for peptides expressed in the neurons of a deceased Alzheimer's patient that had somehow survived the disease process. The neurons that were still alive expressed a previously unknown peptide. They named it Humanin.
What made this discovery significant was not just what it was, but where it came from. Humanin is encoded by the 16S ribosomal RNA region of mitochondrial DNA — making it the first peptide known to be encoded by mitochondrial DNA with biological activity outside the mitochondria itself. This challenged the prevailing view that the mitochondrial genome was a simple, limited system encoding only 13 proteins for energy production.
Humanin is conserved across many species, found in blood and tissues, and its levels decline with age across multiple organisms. The naked mole-rat — one of nature's most remarkable longevity outliers — maintains unusually stable humanin levels throughout its lifespan. Children of human centenarians have significantly higher circulating humanin levels than age-matched controls. These observations don't prove causation, but they form a compelling pattern.
Unlike MOTS-c (which primarily influences metabolism via AMPK) or SS-31 (which stabilises mitochondrial structure), Humanin's primary role is cytoprotection — preventing cell death, particularly in neurons and other high-energy tissues. It achieves this through several converging mechanisms.
A key distinction from MOTS-c: Humanin has identified cell-surface receptors, which gives researchers more tools to study its pharmacology and develop analogues. The potent analogue HNG (where serine 14 is replaced by glycine) shows significantly stronger activity than native Humanin and is used in most animal longevity studies. Much of what the community discusses as "humanin" research actually used HNG.
Humanin has one of the most compelling origin stories and longevity correlations of any peptide in this book — found in surviving Alzheimer's neurons, higher in centenarian children, stable in the world's longest-lived rodent. The neuroprotective mechanism is well-characterised, the Alzheimer's animal data is consistent, and there is genuine human genetic evidence linking humanin levels to cognitive ageing.
The gap between that compelling picture and validated therapeutic use is, however, very wide. No human being has been given exogenous humanin in a published clinical trial. The longevity correlations, however striking, are observational. Most of the quantitative animal research used the HNG analogue, not native humanin. Community-available humanin comes from grey-market sources with no quality verification.
Of the three mitochondrial-derived peptides covered in Part Three (alongside SS-31 and MOTS-c), humanin has the most intriguing longevity biology — and the least actionable human evidence. It is a peptide to watch closely as clinical research develops, rather than to use confidently now.